Purine-Based TLR9 Antagonists for Autoimmune Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions involving untoward immune hyperactivity, such as autoimmune diseases, are limited in effectively inhibiting TLR9-mediated immune responses without causing significant cytotoxicity.
Innovation Solution
Development of novel purine-based compounds, specifically 6-(piperazin-1-yl)-9H-purin-2-amino compounds, which act as TLR9 antagonists, inhibiting immune stimulation through TLR9 signaling while maintaining low cytotoxicity in human cell lines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used to inhibit TLR9-mediated immune responses, then immune hyperactivity is reduced, but cytotoxicity increases
Solution Approach 1:
The patent modifies chemical parameters by developing purine-based compounds with specific structural features (6-(piperazin-1-yl)-9H-purin-2-amino configuration) to achieve selective inhibition of TLR9 signaling. This chemical parameter optimization allows the compounds to effectively block TLR9-mediated immune responses while maintaining low cytotoxicity, resolving the contradiction between therapeutic efficacy and cellular safety
Solution Approach 2:
The invention applies local quality by designing compounds with specific functional groups positioned at particular locations on the purine scaffold. The piperazin-1-yl group at position 6 and amino group at position 2 create localized interaction sites that selectively engage TLR9 receptor pockets, enabling targeted immune modulation without broad cellular toxicity
2Reliability
If current therapeutic agents are used to treat autoimmune diseases, then immune response modulation is achieved, but therapeutic effectiveness is limited
Solution Approach 1:
The patent achieves enhanced therapeutic effectiveness by optimizing key parameters of the purine-based compounds, including molecular weight, lipophilicity, and functional group configuration. These parameter optimizations improve both the potency of TLR9 inhibition and the pharmacokinetic properties, enabling effective treatment of autoimmune conditions with better therapeutic indices than conventional agents
Data Source
AI summary
The present invention provides novel purine based compounds of formula 1, method of preparation of purine based compounds and its composition useful for inhibiting signalling through Toll-like receptors. These compounds are useful in inhibiting immune stimulation involving toll-like receptor 9 (TLR9). These can be used in treatment of autoimmune disease and inflammation where aberrant activation of TLR9 plays role.